Mig- gene silencing inhibits vasculogenic mimicry formation and invasion of glioma U251 cells by suppressing MEK/ERK signaling / 南方医科大学学报

OBJECTIVE@#To investigate the inhibitory effects of silencing migration-inducing gene-7 (Mig-7) on vasculogenic mimicry formation, migration and invasion of human glioma cells and whether MEK/ERK signaling pathway mediates these effects.@*METHODS@#Human glioma U251 cells were infected by lentiviral vectors carrying a small interfering RNA targeting Mig-7 gene (sh-Mig-) or a negative control shRNA (sh-NC), and real-time quantitative PCR was used to detect the expression level of Mig- mRNA in the cells. Three-dimensional culture and Transwell chamber invasion assay were used to observe the effect of Mig- gene silencing on vasculogenic mimicry formation and invasion ability of the U251 cells. Western blotting was performed to detect the changes in the protein expression levels of MEK/ERK in the infected cells.@*RESULTS@#We successfully obtained a U251 cell line with stable low expression of Mig- gene using RNA interference technique. Compared with the cells infected with sh-NC lentivirus and the non- infected cells, U251 cells infected with the lentiviral vector carrying sh-Mig- showed significantly decreased expression level of Mig- ( < 0.01) with obviously lowered vasculogenic mimicry formation and invasion abilities ( < 0.05). Mig- silencing also significantly lowered the expressions of MEK and ERK proteins in U251 cells ( < 0.05).@*CONCLUSIONS@#Silencing of Mig-7 gene inhibits vasculogenic mimicry formation and invasion of U251 cells possibly by suppressing MEK/ERK signaling, suggesting the important role of Mig-7 gene in vasculogenic mimicry formation and invasion of human glioma cells.

Discussion on Issues Concerning Chinese Pharmaceutical Enterprises'Drug Patents / 中国药房

OBJECTIVE:To enhance the competitive edge of Chinese pharmaceutical enterprises.METHODS:Patents problems confronted by Chinese pharmaceutical enterprises were analyzed in terms of the research and development and patent protection of the original new drugs,the administrative protection and patent protection of drugs,patent documentation in?formation,patent strategy and patent talents,etc.RESULTS&CONCLUSION:Chinese pharmaceutical enterprises should highlight the patent problems and apply patent strategy to achieve competitive advantage.